MAT 9001

Drug Profile

MAT 9001

Alternative Names: MAT-9001

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Matinas BioPharma
  • Class Antihyperlipidaemics; Omega 3 fatty acids
  • Mechanism of Action Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Hypertriglyceridaemia
  • Preclinical Dyslipidaemias

Most Recent Events

  • 12 Sep 2017 Matinas BioPharma completes a phase I trial for Hypertriglyceridaemia in Canada (PO)
  • 20 Aug 2015 MAT 9001 is available for licensing as of 18 Aug 2015.
  • 15 Jun 2015 Additional pharmacodynamics data from a phase I trial in hypertriglyceridaemia released by Matinas BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top